Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tricortin 1000 for chronic low back pain
2024-512292-12-00Phase 4Authorised
- Sponsor
- Fidia Farmaceutici
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Tricortin in chronic low back pain (CLBP) (3 arms), sponsored by Fidia Farmaceutici. Primary endpoint: Mean change from baseline to Day 15 in NRS-11. Planned start Dec 2024; status: authorised.
02
Drugs
Tricortin
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on 2024-512292-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512292-12-00.